Swase Terkimbi Dominic, Fasogbon Ilemobayo Victor, Eseoghene Ifie Josiah, Etukudo Ekom Monday, Mbina Solomon Adomi, Joan Chebet, Dangana Reuben Samson, Anyanwu Chinyere, Vandu Comfort Danchal, Agbaje A B, Shinkafi Tijjani Salihu, Abubarkar Ibrahim Babangida, Aja Patrick Maduabuchi
Department of Biochemistry, Faculty of Biomedical Science, Kampala International University Western Campus, Ishaka, Uganda.
Department of Anatomy, Kampala International University, Western Campus, Ishaka, Bushenyi, Uganda.
BMC Cancer. 2025 Feb 5;25(1):202. doi: 10.1186/s12885-025-13516-2.
Human papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection present a significant impact on women's health globally, especially in immunocompromised individuals. HIV-induced immunosuppression promotes the persistence of high-risk HPV infection and increased the progression to cervical cancer. The aim of this systematic review was to assessed the impact of HPV/HIV co-infection on the prevalence and distribution of HR-HPV genotypes, the level of immunosuppression and expression of cervical cancer biomarkers.
The article selection method for this review was based on the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. The total of eighty-four (84) articles from standard electronic databases mainly Web of Science, PubMed, and Scopus were extracted and reviewed. The articles were published in English between 2008 and 2024 and comprised a total of 80023 participants.
The HR-HPV genotypes reported across various studies include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73, and 82. Among HIV positive individuals, the most common circulating HR-HPV genotypes were HPV16, 18, 45, 35, and 58, accounted for 11%, 10%, 9%, 8%, and 8% of cases, respectively. Approximately 29.1% and 30.0% of patients had CD4 counts of 200-400 cells/L and 300-400 cells/L, respectively. The most commonly reported cervical cancer biomarkers were p16INK4a and Ki-67, according to the analysis.
The findings indicate high prevalence of multiple HR-HPV genotypes among HIV positive individuals, indicating the impact of HPV/HIV co-infection on immunosuppression and persistence of HPV infection. The expression of cervical cancer biomarker such as p16INK4a and Ki-67 emphasized target screening and early detection strategy in high-risk population. However, there was no direct impact of HPV/HIV co-infection reported on these biomarkers and required to be studied more especially in people living with HIV.
人乳头瘤病毒（HPV）与人类免疫缺陷病毒（HIV）合并感染对全球女性健康产生重大影响，尤其是在免疫功能低下的个体中。HIV 引起的免疫抑制会促使高危型 HPV 感染持续存在，并增加宫颈癌的进展风险。本系统评价的目的是评估 HPV/HIV 合并感染对高危型 HPV 基因型的流行率和分布、免疫抑制水平以及宫颈癌生物标志物表达的影响。
本综述的文献选择方法基于 2020 年系统评价和 Meta 分析的首选报告项目（PRISMA）标准。从标准电子数据库（主要是 Web of Science、PubMed 和 Scopus）中提取并审查了总共 84 篇文章。这些文章于 2008 年至 2024 年期间以英文发表，共纳入 80023 名参与者。
各项研究报告的高危型 HPV 基因型包括 HPV16、18、31、33、35、39、45、51、52、53、54、56、58、59、66、68、70、73 和 82。在 HIV 阳性个体中，最常见的流行高危型 HPV 基因型是 HPV16、18、45、35 和 58，分别占病例的 11%、10%、9%、8%和 8%。分别约有 29.1%和 30.0%的患者 CD4 细胞计数为 200 - 400 个/微升和 300 - 400 个/微升。根据分析，最常报告的宫颈癌生物标志物是 p16INK4a 和 Ki-67。
研究结果表明 HIV 阳性个体中多种高危型 HPV 基因型的流行率较高，表明 HPV/HIV 合并感染对免疫抑制和 HPV 感染持续存在的影响。p16INK4a 和 Ki-67 等宫颈癌生物标志物的表达强调了高危人群中的靶向筛查和早期检测策略。然而，尚未报告 HPV/HIV 合并感染对这些生物标志物有直接影响，需要在 HIV 感染者中进行更多研究。
